has received research support from Novo Nordisk, Fractyl, AstraZeneca, Congruence Therapeutics, Eli Lilly, Bullfrog AI, Glyscend Therapeutics and Amgen
While these observational data cannot definitively establish causality and may be subject to residual confounding despite sophisticated analytical approaches, the consistency of findings across multiple large, geographically diverse cohorts using different methodologies substantially strengthens confidence in the hepatoprotective benefits of GLP-1-based therapies
Even if they came from a licensed pharmacy, these mixtures are often not approved for safety and effectiveness by federal agencies like the Food and Drug Administration
A 1 mg total draw contains 500 mcg of BPC-157 and 500 mcg of TB-500
Some forum discussions focus on safety concerns, like if BPC-157 causes cancer
At my practice, every GLP-1 consultation is individualized